ASERTAA研究:非裔美国肾移植受者中速释与他克莫司缓释制剂的药物遗传学交叉试验结果
ASERTAA是一项随机前瞻性交叉研究,纳入50例稳定使用速释他克莫司(IR-Tac)的非裔美国维持性肾移植受者,比较IR-Tac与缓释他克莫司(LCPT)的24小时药代动力学参数。约80%受试者携带CYP3A5*1等位基因(快代谢型)。快代谢型与非快代谢型在IR-Tac或LCPT给药期间的AUC0-24和Cmin无显著差异;IR-Tac给药时快代谢型Cmax比非快代谢型高33%(P=0.04),LCPT给药时差异为11%(P=0.4)。结论认为LCPT的延迟吸收可减弱这种药物遗传学效应。
要点
- 非裔美国肾移植受者中约80%为CYP3A5快代谢型,使用IR-Tac达治疗谷浓度时峰浓度显著更高。
- IR-Tac给药时快代谢型Cmax比非快代谢型高33%(P=0.04),LCPT给药时差异仅11%(P=0.4)。
- IR-Tac与LCPT在快代谢型与非快代谢型间的AUC0-24和Cmin无显著差异。
核心结论
- 在多数非裔美国人中,使用IR-Tac达到治疗性他克莫司谷浓度会导致显著更高的峰浓度,可能放大毒性和不良结局风险。
- LCPT的延迟吸收可减弱这种药物遗传学效应。
研究设计与样本
- 随机前瞻性交叉研究,纳入50例稳定使用IR-Tac的非裔美国维持性肾移植受者。
- 受试者随机分为先继续IR-Tac(第1-7天)后换用LCPT(第8天),或先使用LCPT(第1-7天)后换用IR-Tac(第8天);LCPT剂量为IR-Tac总日剂量的85%。
主要发现
- 约80%的受试者携带CYP3A5*1等位基因(CYP3A5快代谢型)。
- 在IR-Tac或LCPT给药期间,CYP3A5快代谢型与非快代谢型之间的AUC0-24或Cmin均无显著差异。
- IR-Tac给药时,快代谢型的他克莫司Cmax比非快代谢型高33%(P=0.04)。
- LCPT给药时,快代谢型与非快代谢型的Cmax差异为11%(P=0.4)。
关键数值与推荐
- LCPT剂量为IR-Tac总日剂量的85%。
- IR-Tac给药时快代谢型Cmax比非快代谢型高33%(P=0.04);LCPT给药时差异为11%(P=0.4)。
临床怎么用
- 对于CYP3A5快代谢型的非裔美国肾移植受者,使用IR-Tac达到目标谷浓度时需关注峰浓度过高风险。
- LCPT的延迟吸收特性可能减轻快代谢型患者的峰浓度差异,或可作为调整策略的参考。
局限性
- 本研究主要是药物遗传学研究而非疗效研究,随访期过短,未能 capture 临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Differences in tacrolimus dosing across ancestries is partly attributable to polymorphisms in CYP3A5 genes that encode tacrolimus-metabolizing cytochrome P450 3A5 enzymes. The CYP3A5*1 allele, preponderant in African Americans, is associated with rapid metabolism, subtherapeutic concentrations, and higher dose requirements for tacrolimus, all contributing to worse outcomes. Little is known about the relationship between CYP3A5 genotype and the tacrolimus pharmacokinetic area under the curve (AUC) profile in African Americans or whether pharmacogenetic differences exist between conventional twice-daily, rapidly absorbed, immediate-release tacrolimus (IR-Tac) and once-daily extended-release tacrolimus (LifeCycle Pharma Tac [LCPT]) with a delayed absorption profile. STUDY DESIGN: Randomized prospective crossover study. SETTING & PARTICIPANTS: 50 African American maintenance kidney recipients on stable IR-Tac dosing. INTERVENTION: Recipients were randomly assigned to continue IR-Tac on days 1 to 7 and then switch to LCPT on day 8 or receive LCPT on days 1 to 7 and then switch to IR-Tac on day 8. The LCPT dose was 85% of the IR-Tac total daily dose. OUTCOMES: Tacrolimus 24-hour AUC (AUC0-24), peak and trough concentrations (Cmax and Cmin), time to peak concentration, and bioavailability of LCPT versus IR-Tac, according to CYP3A5 genotype. MEASUREMENTS: CYP3A5 genotype, 24-hour tacrolimus pharmacokinetic profiles. RESULTS: ∼80% of participants carried the CYP3A5*1 allele (CYP3A5 expressers). There were no significant differences in AUC0-24 or Cmin between CYP3A5 expressers and nonexpressers during administration of either IR-Tac or LCPT. With IR-Tac, tacrolimus Cmax was 33% higher in CYP3A5 expressers compared with nonexpressers (P=0.04): With LCPT, this difference was 11% (P=0.4). LIMITATIONS: This was primarily a pharmacogenetic study rather than an efficacy study; the follow-up period was too short to capture clinical outcomes. CONCLUSIONS: Achieving therapeutic tacrolimus trough concentrations with IR-Tac in most African Americans results in significantly higher peak concentrations, potentially magnifying the risk for toxicity and adverse outcomes. This pharmacogenetic effect is attenuated by delayed tacrolimus absorption with LCPT. TRIAL REGISTRATION: Registered at ClinicalTrials.gov, with study number NCT01962922.
引用
- Trofe-Clark J, Brennan DC, West-Thielke P, et al. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. Am J Kidney Dis. 2017. PMID: 29162334. doi:10.1053/j.ajkd.2017.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。